NeuroVive starts Investor Relations Partnership with Laika Consulting

NeuroVive Pharmaceutical AB (publ) has initiated a collaboration within investor
relations communication with Laika Consulting, a company that specializes in
helping companies and other entities with their financial communication.
The collaboration will start immediately and signals the beginning of an
investor relations program to create a better and clearer dialogue with
NeuroVive´s shareholders and the equity market at large. The first step will be
to conduct a survey with NeuroVive´s over 2 500 shareholders and compile
valuable suggestions for the future work at hand.

“NeuroVive is at a very interesting stage, and I am really looking forward to
the rest of this year. It feels like a natural step to start this collaboration
with Laika Consulting to strengthen our communication, and at the same time make
it possible for me to focus on the day to day daily running of the business”,
says Mikael Bronnegard, CEO of NeuroVive.

“I am very excited to accept the challenge to take NeuroVive´s Investor
Relations communication to a whole new level. Our nine years of experience with
financial communication, especially within the financial business, makes me
certain that we are the right collaboration partner for this assignment”, says
Ingmar Rentzhog, CEO of Laika Consulting.

To achieve a faster response time on questions from shareholders, media and
other interested parties, the following dedicated IR channels have been created:

Tel: +46 (0)46-275 62 21 and ir@neurovive.com

You can also contact any of the following persons for more information:

Mikael Bronnegard, CEO NeuroVive Pharmaceutical AB (publ)

Telephone:+46 (0)46-275 62 20, Email: info@neurovive.com

Ingmar Rentzhog, CEO Laika Consulting AB

Telephone: +46(0)8-440 82 42, Email: vd@laika.se

About NeuroVive Pharmaceutical AB (publ)

NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. NeuroVive´s product
portfolio contains drug candidates developed to prevent the death of
mitochondria in distressed cells and the subsequent cascade of intracellular
biochemical events that lead to secondary tissue damage following an acute
cardiac or traumatic brain injury. NeuroVive is also working on several other
projects aimed at cellular protection and the treatment of mitochondria-related
energy regulation disorders.

About Laika Consulting

Laika Consulting is one of Sweden’s largest independent communication companies
within the financial business. Laika consists of established experts on
financial communication for both financial and listed companies, and acts as a
natural link between its clients and their customers and shareholders. Laika is
regularly commissioned by banks, insurance companies, capital managers,
financial advisors and listed companies in need of financial communication.

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund

Telephone: +46 (0)46-275 62 20 (operator), Fax: +46 (0)46-888 83 48

Email: info@neurovive.com

Website: www.neurovive.com